A Cure for Cancer

Medical marijuana studies.

Moderator: administration

A Cure for Cancer

Postby palmspringsbum » Thu Jul 13, 2006 8:27 pm

NORML wrote:Cannabinoids Curb Brain Tumor Growth, First-Ever Patient Trial Shows

The National Organization for the Repeal of Marijuana Laws

July 13, 2006 - Madrid, Spain



Madrid, Spain: THC administration decreases recurrent glioblastoma multiforme (GBM) tumor growth in humans, according to the findings of the first-ever clinical trial assessing cannabinoids' anti-tumor action.

Investigators at Complutense University in Spain administered THC intratumorally in nine patients diagnosed with recurrent GBM, an extremely rapid and lethal form of brain tumor. Patients in the study had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumor progression. THC treatment was associated with reduced tumor cell proliferation in two subjects, authors reported.

Investigators did not determine whether THC positively impacted patients' survival, though they did conclude that cannabinoid therapy does not facilitate cancer growth or decrease patients' life expectancy. Median survival of the cohort from the beginning of cannabinoid administration was 24 weeks, and two patients survived for approximately one year. Survival for GBM patients following diagnosis is typically six to twelve months.

Researchers speculated that newly diagnosed glioma patients may respond more favorably to cannabinoid-based therapies.

Investigators also reported that THC demonstrated significant anti-proliferative activity on human GBM cells in culture.

"The fair safety profile of THC, together with its possible anti-proliferative action on tumor cells reported here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids," investigators concluded.

In 2005, investigators at the California Pacific Medical Center Research Institute in San Francisco reported that THC selectively decreases the proliferation of malignant cells and induces cell death in human GBM cell lines. Healthy cells in the study were unaffected by THC administration.

Separate preclinical studies indicate that cannabinoids and endocannabinoids can stave off tumor progression and trigger cell death in other cancer cell lines, including breast carcinoma, prostate carcinoma, colectoral carcinoma, skin carcinoma, and pancreatic adenocarcinoma.

For more information, please contact <a class=postlink href=mailto:paul@norml.org>Paul Armentano</a>, NORML Senior Policy Analyst, at (202) 483-5500. Full text of the study, "A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme," appears in the July issue of the British Journal of Cancer. Abstracts of the study are available online at: http://www.nature.com/bjc/journal/v95/n2/abs/6603236a.html. Additional information on cannabinoids' anti-cancer properties is available in NORML's report, "Cannabinoids as Cancer Hope," online at: http://www.norml.org/index.cfm?Group_ID=6814




<span class=postbold>See Also</span>: Lung Cancer
Last edited by palmspringsbum on Sun Aug 06, 2006 4:51 pm, edited 1 time in total.
User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Medical marijuana research takes a few surprising turns

Postby palmspringsbum » Tue Jul 18, 2006 12:31 pm

The San Francisco Examiner wrote:Medical marijuana research takes a few surprising turns

Karl B. Hille, The Examiner
Jul 18, 2006 5:00 AM (10 hrs ago)
Current rank: # 4 of 5,240 articles

BALTIMORE - Research being conducted around the globe hints at the potential for marijuana to treat cancer, as well as lead to pre-cancerous conditions.

A Spanish paper published in the journal Nature Reviews-Cancer explored the potential for the active ingredient in marijuana to inhibit cancer growth, while Johns Hopkins researchers are studying compounds that might render the drug ineffective for those seeking its high.

“Further basic research and more exhaustive clinical trials are still required before cannabinoids can be routinely used in cancer therapy,” wrote Manuel Guzman in his research paper “Cannabinoids: Potential anticancer agents.”

A biochemist with the Complutense University in Madrid, Guzman identified the process by which cannabinoids, found in many forms in marijuana, can inhibit cell growth and trigger cell death — processes that can get out of control in cancerous cells. One specific compound, delta 9-tetrahydrocannabinol, has been proven a valuable compound in fighting nausea and vomiting, stimulating appetite and controlling pain, he writes.

Don’t look for the federal government to approve marijuana cigarettes any time in the foreseeable future, said Dr. Richard Wahl, a researcher with Johns Hopkins in Baltimore. “There are all kinds of compounds in smoke. For medical purposes, you want to be able to isolate the compounds that have the desired effect,” he said.

In addition, marijuana smoke has been known to create conditions that lead to lung cancer, though scientists have not positively linked the drug to cancer, according to The Archives of Internal Medicine.

Wahl and his colleagues have mapped parts of the brain that respond to cannabinoids by tailoring compounds with radioactive tags for injection, then reading them through positive electron tomography — PET scans. Through their research, scientists now know these compounds predominantly affect parts of the brain that influence pleasure, memory, thought, concentration, sensory and time perception, and coordinated movement.

Some types of cancer, including breast cancer, also have cannabinoid receptors on their surfaces, he said.

“There are also other compounds that bind to these receptors,” Wahl said.

They are looking for a National Institutes of Health grant to identify drugs that can block those receptors, rendering the marijuana ineffective.

khille@baltimoreexaminer.com

Examiner



<span class=postbold>See Also</span>: Brain's Receptors Sensitive To Pot May 'open Door' In Treating Drug Dependence, Brain Disorders
User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Chemotherapy harms the brain, researchers find

Postby palmspringsbum » Fri Dec 01, 2006 5:22 pm

The San Francisco Chronicle wrote:Chemotherapy harms the brain, researchers find

3 studies uncover reasons for mental fuzziness that doctors often dismiss

- Thomas H. Maugh II, Los Angeles Times
Friday, December 1, 2006
The San Francisco Chronicle

Cancer chemotherapy can severely damage the brain, killing crucial brain cells and causing key parts of the brain to shrink, according to two studies released this week.

The new findings add to a growing body of evidence suggesting that the phenomenon of "chemobrain" -- the mental fuzziness, memory loss and cognitive impairment often reported by cancer patients but often dismissed by oncologists -- is a serious problem.

"Those of us on the front lines have known this for a long time, but now we have some neuropathological evidence that what we are seeing involves an anatomic change," said Dr. Stewart Fleishman, director of cancer supportive services at Beth Israel Medical Center and St. Luke's-Roosevelt Hospital Center in New York.

The new studies should help convince physicians who are skeptical about the phenomenon, said Fleishman, who was not involved in the research.

Because chemotherapy is such a crucial component of cancer treatment and cannot be abandoned, scientists are calling for increased research on shielding the brain from its toxic effects and developing more-selective cancer drugs.

"There are no easy answers," said Dr. Patricia Duffner of the State University of New York at Buffalo School of Medicine.

Several studies have suggested that from 40 to 80 percent of cancer patients receiving chemotherapy suffer from chemobrain. The problem is particularly severe for breast cancer patients, Fleishman noted, because the treatment induces hormonal changes typical of menopause, and these changes can also produce memory problems.

It has also become more common as chemotherapy has increasingly been used at an early stage of treatment rather than as a treatment of last resort.

Dr. Masatoshi Inagaki of the National Cancer Center Hospital in Shikoku, Japan, led a team that used high-resolution magnetic resonance imaging to compare the brains of 51 women who received chemotherapy for breast cancer with those of 54 breast cancer patients who had surgery only.

Inagaki and his colleagues reported Monday in the current issue of the journal Cancer that, one year after treatment, key areas of the brain involved in cognitive processes were significantly smaller in the women who had chemotherapy.

The greater the volume loss in those areas, the team found, the greater the difficulty shown by the women in tests of concentration and memory.

In the second study, biomedical geneticist Mark Noble and his colleagues at the University of Rochester Medical Center exposed human brain cells and brain tumor cells grown in a laboratory dish to three of the most commonly used cancer drugs -- carmustine, cisplatin and cytarabine.

They reported Thursday in the Journal of Biology that low doses of the drugs caused a 60 to 90 percent reduction in the viability of the brain cells, but had little effect on the tumor cells. To kill 40 to 80 percent of the tumor cells required drug doses that killed 70 to 100 percent of the brain cells.

Even though the cancer drugs are targeted at replicating cancer cells, the researchers found that both replicating and nonreplicating brain cells were killed.

The team then administered the drugs to mice and autopsied their brains. They found that the drugs killed cells in several regions of the brain and that cells continued dying, in some cases, for several weeks after the cessation of treatment.

"This is the first study that puts chemobrain on a sound scientific footing," Noble said.

In a third study, reported last month in the journal Breast Cancer Research and Treatment, Dr. Daniel Silverman and his colleagues at UCLA used positron emission tomography to study brain metabolism in 16 women who underwent chemotherapy and surgery for breast cancer and five who had surgery only. They also studied 13 women who did not have cancer and received no treatment.

They took images of the women's brains at rest and while they were performing exercises in short-term memory. They found that the women who received chemotherapy had lower metabolism rates while they were resting than did the women in the other two groups. The lower the resting rate, the more difficulty the women had on the memory tests.

Page A - 8
URL: http://sfgate.com/cgi-bin/article.cgi?f ... MN9V51.DTL

User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Study: Marijuana Appears to Slow Cancer Growth in Laboratory

Postby palmspringsbum » Thu Dec 27, 2007 6:26 pm

FoxNews wrote:Study: Marijuana Appears to Slow Cancer Growth in Laboratory Setting

FoxNews.com
Thursday , December 27, 2007


<span class=postbigbold>Certain marijuana components may suppress the tumors of highly invasive cancers, a new study finds.</span>

In laboratory tests, cannabinoids, the active components in marijuana, were found to slow the spread of lung and cervical cancer tumors, according to researchers Robert Ramer and Burkhard Hinz of the University of Rostock in Germany.

Proponents of medical marijuana believe that cannabinoids reduce the side effects of cancer treatment, such as pain, weight loss and vomiting.

The study, published in the Jan. 2 issue of the Journal of the National Cancer Institute, finds that the compounds may also have an anticancer effect; however, more research is needed to determine whether the laboratory results will hold true in humans, the authors wrote.

Click here for the study.

In addition to suppressing tumor cell invasion, cannabinoids also stimulated the expression of TIMP-1, an inhibitor of a group of enzymes involved in tumor cell invasion.

"To our knowledge, this is the first report of TIMP-1-dependent anti-invasive effects of cannabinoids," the authors wrote. "This signaling pathway may play an important role in the antimetastatic action of cannabinoids, whose potential therapeutic benefit in the treatment of highly invasive cancers should be addressed in clinical trials."
User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Inhibition of Cancer Cell Invasion by Cannabinoids

Postby palmspringsbum » Thu Dec 27, 2007 6:34 pm

The Journal of the National Cancer Institute wrote:<span class=postbold>Journal of the National Cancer Institute Advance Access published online on December 25, 2007</span>
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djm268
ARTICLES


Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1


Robert Ramer, Burkhard Hinz

<span class=postbold>Affiliation of authors</span>: Institute of Toxicology and Pharmacology, University of Rostock, Rostock, Germany

<span class=postbold>Correspondence to</span>: Burkhard Hinz, PhD, Institute of Toxicology and Pharmacology, University of Rostock, Schillingallee 70, Rostock D-18057, Germany (e-mail: burkhard.hinz@med.uni-rostock.de).

<span class=postbold>Background</span>: Cannabinoids, in addition to having palliative benefits in cancer therapy, have been associated with anticarcinogenic effects. Although the antiproliferative activities of cannabinoids have been intensively investigated, little is known about their effects on tumor invasion.

<span class=postbold>Methods</span>: Matrigel-coated and uncoated Boyden chambers were used to quantify invasiveness and migration, respectively, of human cervical cancer (HeLa) cells that had been treated with cannabinoids (the stable anandamide analog R(+)-methanandamide [MA] and the phytocannabinoid 9-tetrahydrocannabinol [THC]) in the presence or absence of antagonists of the CB1 or CB2 cannabinoid receptors or of transient receptor potential vanilloid 1 (TRPV1) or inhibitors of p38 or p42/44 mitogen–activated protein kinase (MAPK) pathways. Reverse transcriptase–polymerase chain reaction (RT-PCR) and immunoblotting were used to assess the influence of cannabinoids on the expression of matrix metalloproteinases (MMPs) and endogenous tissue inhibitors of MMPs (TIMPs). The role of TIMP-1 in the anti-invasive action of cannabinoids was analyzed by transfecting HeLa, human cervical carcinoma (C33A), or human lung carcinoma cells (A549) cells with siRNA targeting TIMP-1. All statistical tests were two-sided.

<span class=postbold>Results</span>: Without modifying migration, MA and THC caused a time- and concentration-dependent suppression of HeLa cell invasion through Matrigel that was accompanied by increased expression of TIMP-1. At the lowest concentrations tested, MA (0.1 µM) and THC (0.01 µM) led to a decrease in invasion (normalized to that observed with vehicle-treated cells) of 61.5% (95% CI = 38.7% to 84.3%, P < .001) and 68.1% (95% CI = 31.5% to 104.8%, P = .0039), respectively. The stimulation of TIMP-1 expression and suppression of cell invasion were reversed by pretreatment of cells with antagonists to CB1 or CB2 receptors, with inhibitors of MAPKs, or, in the case of MA, with an antagonist to TRPV1. Knockdown of cannabinoid-induced TIMP-1 expression by siRNA led to a reversal of the cannabinoid-elicited decrease in tumor cell invasiveness in HeLa, A549, and C33A cells.

<span class=postbold>Conclusion</span>: Increased expression of TIMP-1 mediates an anti-invasive effect of cannabinoids. Cannabinoids may therefore offer a therapeutic option in the treatment of highly invasive cancers.


<span class=postbigbold>CONTEXT AND CAVEATS</span>

<span class=postbold>Prior knowledge</span>

Treatment with cannabinoids had been shown to reduce the invasiveness of cancer cells, but the cellular mechanisms underlying this effect were unclear.

<span class=postbold>Study design</span>

Cancer cells treated with combinations of cannabinoids, antagonists of cannabinoid receptors, and siRNA to tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) were assessed for invasiveness, protein expression, and activation of signal transduction pathways.

<span class=postbold>Contribution</span>

The expression of TIMP-1 was shown to be stimulated by cannabinoid receptor activation and to mediate the anti-invasive effect of cannabinoids.

<span class=postbold>Implications</span>

Clarification of the mechanism of cannabinoid action may help investigators to explore their therapeutic benefit.

<span class=postbold>Limitations</span>

The relevance of the findings to the behavior of tumor cells in vivo remains to be determined.



Manuscript received April 24, 2007; revised September 24, 2007; accepted November 16, 2007.


User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Breakthrough Discovered in Medical Marijuana Cancer Treatmen

Postby palmspringsbum » Wed Jan 16, 2008 11:10 am

The Salem-News.com wrote:Salem-News.com (Jan-11-2008 11:47)

Breakthrough Discovered in Medical Marijuana Cancer Treatment

Tim King Salem-News.com

<span class=postbigbold>Researchers learned that cannabinoids have been associated with anti-carcinogenic effects, which are responsible in preventing or delaying the development of cancer.</span>

<table class=posttable align=right width=300><tr><td class=postcell><img class=postimg width=300 src=/bin/caduceus_big.jpg></td></tr></table>(SALEM, Ore.) - A new study reveals that Medical Marijuana can be an effective treatment for cancer, that is the word announced by doctors in Germany who concluded that this clarification of the mechanism of cannabinoid action may help investigators to further explore their therapeutic benefit.

The medical article was originally published in the <span class=postbold>Journal of the National Cancer Institute Advance Access</span> and online on December 25th 2007.

Cancer cells that were treated with combinations of cannabinoids, antagonists of cannabinoid receptors, and small interfering ribo nucleic acid or 'siRNA' to tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) were assessed for invasiveness, protein expression, and activation of signal transduction pathways.

The biggest contribution of this breakthrough discovery, is that the expression of TIMP-1 was shown to be stimulated by cannabinoid receptor activation and to mediate the anti-invasive effect of cannabinoids.

In other words, they learned that treatment with cannabinoids, one of the active ingredients of the medicinal side of marijuana, has been shown to reduce the invasiveness of cancer cells. Prior to now the cellular mechanisms underlying this effect were unclear and the relevance of the findings to the behavior of tumor cells in vivo remains to be determined.

It is already known that marijuana can stimulate the appetite of patients, but researchers have learned that cannabinoids, in addition to having palliative benefits in cancer therapy, have been associated with anti-carcinogenic effects, which are responsible in preventing or delaying the development of cancer.

"Although the anti-proliferative activities of cannabinoids have been intensively investigated, little is known about their effects on tumor invasion," the article stated.

<span class=postbigbold>Method</span>

In this now completed round of research, Matrigel-coated and uncoated Boyden chambers were used to quantify invasiveness and migration, respectively, of human cervical cancer 'HeLa' cells that had been treated with cannabinoids.

The stable anandamide analog R(+)-methanandamide 'MA' and the phytocannabinoid 9-tetrahydrocannabinol 'THC' in the presence or absence of antagonists of the CB1 or CB2 cannabinoid receptors or of transient receptor potential vanilloid 1 (TRPV1) or inhibitors of p38 or p42/44 mitogen–activated protein kinase (MAPK) pathways.

A method known as 'reverse transcriptase–polymerase chain reaction' and immunoblotting were used to assess the influence of cannabinoids on the expression of matrix metalloproteinases and endogenous tissue inhibitors. The role of TIMP-1 in the anti-invasive action of cannabinoids was analyzed by transfecting HeLa, human cervical carcinoma, or human lung carcinoma cells cells with siRNA targeting TIMP-1.

They say all statistical tests were two-sided.

<span class=postbigbold>Results</span>

Without modifying migration, MA and THC caused a time and concentration-dependent suppression of HeLa cell invasion through Matrigel that was accompanied by increased expression of TIMP-1.

At the lowest concentrations tested, MA and THC led to a decrease in cell invasion.

"The stimulation of TIMP-1 expression and suppression of cell invasion were reversed by pretreatment of cells with antagonists to CB1 or CB2 receptors, with inhibitors of MAPKs, or, in the case of MA, with an antagonist to TRPV1. Knockdown of cannabinoid-induced TIMP-1 expression by siRNA led to a reversal of the cannabinoid-elicited decrease in tumor cell invasiveness in HeLa, A549, and C33A cells."

The researchers concluded that increased expression of TIMP-1 mediates an anti-invasive effect of cannabinoids. That means that in our future, cannabinoids may offer a therapeutic option in the treatment of highly invasive cancers.

<hr class=postrule><small>Special thanks to the JNCI Journal of the National Cancer Institute, and to Burkhard Hinz, PhD, Institute of Toxicology and Pharmacology, University of Rostock and the affiliation of authors: Institute of Toxicology and Pharmacology, University of Rostock in Rostock, Germany.

The original report published by Oxford University Press was titled, "Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1Robert Ramer, Burkhard Hinz."</small>
User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Marijuana does not increase risk of head & neck cancer

Postby palmspringsbum » Mon Mar 10, 2008 9:00 pm

EurekAlert! wrote:Public release date: 4-Mar-2008

Contact: Jessica Mikulski
newsroom@entnet.org
703-519-1549
American Academy of Otolaryngology, Head and Neck Surgery

Small study shows marijuana does not increase risk of head, neck cancer

<span class=postbigbold>New research from Otolaryngology -- Head and Neck Surgery</span>

Alexandria, VA – Smoking marijuana (cannabis) does not increase the user’s risk of head and neck cancer, according to a new study published in the March 2008 issue of Otolaryngology – Head and Neck Surgery.

The small sample study, authored by researchers from New Zealand and Great Britain, found that among 75 cases of head and neck cancer, the relative risk of smoking cannabis and contracting head and neck cancer in marijuana users was the same (1.0) as in those who had never smoked cannabis. These results differ from the relative risk of contracting cancer from smoking cigarettes (2.1) and the heavy consumption of alcohol (5.7), compared with those who abstained from those activities.

However, due to the limits of the study, the authors cannot exclude other possible effects, and recommend a larger study.

Cancers of the head and neck, with more than 500,000 new cases diagnosed each year worldwide, represent the fourth most common type of cancer. It is estimated that more than 13,000 people will die from head and next cancer each year in the United States alone.

<center>###</center>

Otolaryngology – Head and Neck Surgery is the official scientific journal of the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS). The study authors are Sarah Aldington, BMBS; Matire Harwood, MBChB; Brian Cox, PhD; Mark Weatherall, FRACP; Lutz Beckertz, MD; Anna Hansell, PhD; Alison Prithchard; Geoffrey Robinson, FRACP; and Richard Beasley, DSc. The study was conducted on behalf of the Cannabis and Respiratory Disease Research Group.

AAO-HNS will join in observing Oral, Head, and Neck Cancer Awareness Week (OHNCAW) beginning April 21, 2008 and ending April 27, 2008. More information on the week’s activities can be found at http://www.headandneck.org/.

Reporters wishing to obtain the full study may contact Matt Daigle at 1-703-519-1563, or at newsroom@entnet.org. Experts are also available to discuss the treatment and prevention of head and neck cancer.

About the AAO-HNS

The American Academy of Otolaryngology – Head and Neck Surgery ( www.entnet.org ), one of the oldest medical associations in the nation, represents more than 13,000 physicians and allied health professionals who specialize in the diagnosis and treatment of disorders of the ears, nose, throat, and related structures of the head and neck. The Academy serves its members by facilitating the advancement of the science and art of medicine related to otolaryngology and by representing the specialty in governmental and socioeconomic issues. The organization’s mission: “Working for the Best Ear, Nose, and Throat Care.”

User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Pot Shrinks Tumors; Government Knew in '74

Postby palmspringsbum » Tue Mar 10, 2009 4:49 pm

Alternet wrote:Pot Shrinks Tumors; Government Knew in '74

By Raymond Cushing, AlterNet
Posted on May 31, 2000, Printed on March 10, 2009


The term medical marijuana took on dramatic new meaning in February, 2000 when researchers in Madrid announced they had destroyed incurable brain tumors in rats by injecting them with THC, the active ingredient in cannabis.

The Madrid study marks only the second time that THC has been administered to tumor-bearing animals; the first was a Virginia investigation 26 years ago. In both studies, the THC shrank or destroyed tumors in a majority of the test subjects.

Most Americans don't know anything about the Madrid discovery. Virtually no major U.S. newspapers carried the story, which ran only once on the AP and UPI news wires, on Feb. 29, 2000.

The ominous part is that this isn't the first time scientists have discovered that THC shrinks tumors. In 1974 researchers at the Medical College of Virginia, who had been funded by the National Institute of Health to find evidence that marijuana damages the immune system, found instead that THC slowed the growth of three kinds of cancer in mice -- lung and breast cancer, and a virus-induced leukemia.

The DEA quickly shut down the Virginia study and all further cannabis/tumor research, according to Jack Herer, who reports on the events in his book, "The Emperor Wears No Clothes." In 1976 President Gerald Ford put an end to all public cannabis research and granted exclusive research rights to major pharmaceutical companies, who set out -- unsuccessfully -- to develop synthetic forms of THC that would deliver all the medical benefits without the "high."

The Madrid researchers reported in the March issue of "Nature Medicine" that they injected the brains of 45 rats with cancer cells, producing tumors whose presence they confirmed through magnetic resonance imaging (MRI). On the 12th day they injected 15 of the rats with THC and 15 with Win-55,212-2 a synthetic compound similar to THC. "All the rats left untreated uniformly died 12-18 days after glioma (brain cancer) cell inoculation ... Cannabinoid (THC)-treated rats survived significantly longer than control rats. THC administration was ineffective in three rats, which died by days 16-18. Nine of the THC-treated rats surpassed the time of death of untreated rats, and survived up to 19-35 days. Moreover, the tumor was completely eradicated in three of the treated rats." The rats treated with Win-55,212-2 showed similar results.

The Spanish researchers, led by Dr. Manuel Guzman of Complutense University, also irrigated healthy rats' brains with large doses of THC for seven days, to test for harmful biochemical or neurological effects. They found none.

"Careful MRI analysis of all those tumor-free rats showed no sign of damage related to necrosis, edema, infection or trauma ... We also examined other potential side effects of cannabinoid administration. In both tumor-free and tumor-bearing rats, cannabinoid administration induced no substantial change in behavioral parameters such as motor coordination or physical activity. Food and water intake as well as body weight gain were unaffected during and after cannabinoid delivery. Likewise, the general hematological profiles of cannabinoid-treated rats were normal. Thus, neither biochemical parameters nor markers of tissue damage changed substantially during the 7-day delivery period or for at least 2 months after cannabinoid treatment ended."

Guzman's investigation is the only time since the 1974 Virginia study that THC has been administered to live tumor-bearing animals. (The Spanish researchers cite a 1998 study in which cannabinoids inhibited breast cancer cell proliferation, but that was a "petri dish" experiment that didn't involve live subjects.)

In an email interview for this story, the Madrid researcher said he had heard of the Virginia study, but had never been able to locate literature on it. Hence, the Nature Medicine article characterizes the new study as the first on tumor-laden animals and doesn't cite the 1974 Virginia investigation.

"I am aware of the existence of that research. In fact I have attempted many times to obtain the journal article on the original investigation by these people, but it has proven impossible." Guzman said.

In 1983 the Reagan/Bush Administration tried to persuade American universities and researchers to destroy all 1966-76 cannabis research work, including compendiums in libraries, reports Jack Herer, who states, "We know that large amounts of information have since disappeared."

Guzman provided the title of the work -- "Antineoplastic activity of cannabinoids," an article in a 1975 Journal of the National Cancer Institute -- and this writer obtained a copy at the University of California medical school library in Davis and faxed it to Madrid.

The summary of the Virginia study begins, "Lewis lung adenocarcinoma growth was retarded by the oral administration of tetrahydrocannabinol (THC) and cannabinol (CBN)" -- two types of cannabinoids, a family of active components in marijuana. "Mice treated for 20 consecutive days with THC and CBN had reduced primary tumor size."

The 1975 journal article doesn't mention breast cancer tumors, which featured in the only newspaper story ever to appear about the 1974 study -- in the Local section of the Washington Post on August 18, 1974. Under the headline, "Cancer Curb Is Studied," it read in part:

"The active chemical agent in marijuana curbs the growth of three kinds of cancer in mice and may also suppress the immunity reaction that causes rejection of organ transplants, a Medical College of Virginia team has discovered." The researchers "found that THC slowed the growth of lung cancers, breast cancers and a virus-induced leukemia in laboratory mice, and prolonged their lives by as much as 36 percent."

Guzman, writing from Madrid, was eloquent in his response after this writer faxed him the clipping from the Washington Post of a quarter century ago. In translation, he wrote:

"It is extremely interesting to me, the hope that the project seemed to awaken at that moment, and the sad evolution of events during the years following the discovery, until now we once again Œdraw back the veil‚ over the anti-tumoral power of THC, twenty-five years later. Unfortunately, the world bumps along between such moments of hope and long periods of intellectual castration."

News coverage of the Madrid discovery has been virtually nonexistent in this country. The news broke quietly on Feb. 29, 2000 with a story that ran once on the UPI wire about the Nature Medicine article. This writer stumbled on it through a link that appeared briefly on the Drudge Report web page. The New York Times, Washington Post and Los Angeles Times all ignored the story, even though its newsworthiness is indisputable: a benign substance occurring in nature destroys deadly brain tumors.
<small>
Raymond Cushing is a journalist, musician and filmmaker. This article was named by Project Censored as a "Top Censored Story of 2000."
</small>
Where it all comes together...
User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California

Marijuana May Be Used To Kill Cancer Cells

Postby palmspringsbum » Sat Apr 11, 2009 2:41 pm

TestCountry.com wrote:TestCountry.com | April 8, 2009

Marijuana May Be Used To Kill Cancer Cells

Great news for the supporters of medical marijuana; a study conducted by a group of Spanish researchers seem to indicate that there may be a more specific use for the cannabis plant in cancer treatment that goes beyond pain management.

The study indicates that an active ingredient in marijuana, tetrahydrocannabinol (THC), may trigger a natural process that will eventually lead to the death of a cell. The study was reported in the April 1 issue of the Journal of Clinical Investigation.

If the study is pursued further and medical viability is established, medical marijuana may be more than just a way for terminally ill patients to deal with their respective diseases. It will become an erstwhile way to win one’s battle over cancer.

Experiments were conducted at the cellular level, and biopsy tissues taken from two patients with glioblastoma multiforme who were treated with THC were examined. The researchers cultured a human glioma cell line as well as mouse cancer cells and treated a population of cells with THC. Both the process of treatment and the observation of the reaction of both treated and untreated cells were done under an electron microscope and recorded.

It was observed that in cells treated with THC, the introduction of the ingredient triggered a process known as autophagy. Autophagy is a regulated process that is a normal part of cell growth, development and homeostasis. It is a process that will eventually lead to cell death.

It has, however, a rather ambiguous role in the development of diseases, as while it may prevent the growth and spread of certain types of cancers, it can at the same time contribute to the progress of other diseases. This means scientists and medical researchers need to dig into this deeper before doctors can start prescribing joint to patients.

Where it all comes together...
User avatar
palmspringsbum
Site Admin
Site Admin
 
Posts: 2769
Joined: Sun Jun 11, 2006 6:38 pm
Location: Santa Cruz, California


Return to science

Who is online

Users browsing this forum: No registered users and 1 guest

cron